Dexmedetomidine for sedation of patients in the ICU or PICU : review of clinical effectiveness and safety / prepared by Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Government document

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Contributor:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Rapid response report (Canadian Agency for Drugs and Technologies in Health).

NCBI Bookshelf.

Rapid response report: summary with critical appraisal, 1922-8147

NCBI Bookshelf

Language:

English

Subjects (All):

Dexmedetomidine--therapeutic use.

Dexmedetomidine--pharmacology.

Hypnotics and Sedatives--pharmacology.

Critical Care--methods.

Medical Subjects:

Dexmedetomidine--therapeutic use.

Dexmedetomidine--pharmacology.

Hypnotics and Sedatives--pharmacology.

Critical Care--methods.

Physical Description:

1 online resource (1 PDF file (21 pages)) : illustrations.

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, January 2014.

Summary:

Sedation of ICU patients is often essential for ICU patients to maximize survival, reduce ICU and hospital stay, and facilitate mechanical ventilation. The standard of care for sedation include benzodiazepine sedatives and propofol. Some drawbacks of the available sedative agents include patients' agitation and delirium. To overcome these drawbacks, it has been suggested that dexmedetomidine can be an appropriate alternative to traditional sedatives for maintaining light to moderate sedation. However, the Health Canada approved label for dexmedetomidine provides warnings that the drug is associated with hypotension, clinically significant episodes of bradycardia, and sinus arrest. The objective of the current review is to evaluate the evidence surrounding the use of dexmedetomidine for sedation in intensive-care units.

Notes:

"CADTH rapid response service."

"16 January 2014."